AVEO Pharmaceuticals is a biopharmaceutical company seeking to advance targeted medicines for oncology and other unmet medical needs. The Company’s lead candidate is tivozanib, a potent, selective, long half-life inhibitor of vascular endothelial growth factor 1, 2 and 3 receptors, which AVEO is working to develop and commercialize in North America as a treatment for renal cell carcinoma (RCC), hepatocellular carcinoma (HCC) and other cancers. Tivozanib (FOTIVDA®) is approved by the European Commission for the treatment of adult patients with advanced RCC in the European Union plus Norway, New Zealand, and Iceland. AVEO is leveraging or seeks to leverage partnerships to develop and commercialize its pipeline of products and product candidates, including tivozanib in oncology and other indications in various geographies, and ficlatuzumab (HGF MAb) in head and neck cancer, pancreatic cancer and acute myeloid leukemia. AVEO’s earlier-stage pipeline includes AV-203 (anti-ErbB3 MAb), AV-380 (GDF15 MAb) and AV-353 (Notch 3 MAb) for various oncology indications.
- 20 Patients Remain Progression Free on Tivozanib Arm vs. 2 on Sorafenib Arm - - Company Plans to Discuss Updated Results with FDA - - AVEO to Host Conference Call Today at 8:00 am Eastern Time - CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 10, 2019-- AVEO Oncology (NASDAQ: AVEO ) today announced
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 8, 2019-- AVEO Oncology (NASDAQ: AVEO ) today reported financial results for the second quarter ended June 30, 2019 and provided a business update. “As we move toward reporting more mature interim overall survival (OS) results from our TIVO -3 study of
TOKYO & CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 1, 2019-- Kyowa Kirin Co., Ltd. , ( Kyowa Kirin , TYO: 4151) and AVEO Oncology (NASDAQ: AVEO ) announce that they have amended their license agreement to allow Kyowa Kirin to buy back the non-oncology rights of tivozanib in AVEO territories, which